Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 111759000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 18.69% year-over-year to 111759000.0 in Q1 2026; TTM through Mar 2026 was 357482000.0, a 5.86% decrease from a year earlier, with the FY2025 full-year figure at 652819000.0, down 37.16% from the prior year.
• Income from Continuing Operations eased to 111759000.0 in Q1 2026 per VRDN's latest filing, from 99005000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 25693000.0 in Q1 2022 and bottomed at 111759000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 68186000.0 (2023), against an average of 66925000.0.
• Across the five-year window, Income from Continuing Operations plunged 165.39% in 2023 and surged 61.69% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 45592000.0 in 2022, then slumped by 84.64% to 84179000.0 in 2023, then climbed by 6.04% to 79092000.0 in 2024, then retreated by 25.18% to 99005000.0 in 2025, then retreated by 12.88% to 111759000.0 in 2026.
• Per Business Quant, the three latest VRDN Income from Continuing Operations figures stand at 111759000.0 (Q1 2026), 99005000.0 (Q4 2025), and 35052000.0 (Q3 2025).